Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients

Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients - Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018170

Enrollment

180

Registered

2015-07-06

Start date

2015-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Treated with trelagliptin (once weekly) in period 1, teneligliptin (once daily) in period 2, and vildagliptin (twice daily) in period 3. Treated with trelagliptin (once weekly) in period 1, vildaglipt

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients treated with alogliptin

Exclusion criteria

Exclusion criteria: - Patients with severe hepatic, renal, and/or cardiac disease - Patients with hypersentitivity to the agents used in the current study - Patients who are pregnant, breast-feeding or may become pregnant - Patients who are judged by the investigator to be inappropriate for this study for any other reason.

Design outcomes

Primary

Measure	Time frame
Patients' satisfaction	—

Secondary

Measure	Time frame
Adherence Blood glucose	—

Countries

Japan

Contacts

Public ContactToshihiko Shiraiwa

Shiraiwa Medical Clinic Shiraiwa Medical Clinic

shiraiwa@endmet.med.osaka-u.ac.jp072-971-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026